New strategies for the treatment of metastatic bone disease. Review uri icon

Overview

abstract

  • The introduction of bisphosphonates represents an important advance in the care of patients with metastatic bone disease. Nonetheless, we remain unable to prevent metastatic bone destruction. This review will discuss several novel therapies, including inhibitors of receptor activator of nuclear factor-kappabeta, c-Src, mammalian target of rapamycin, cathepsin K, and alpha(5)beta(3) integrins, which could improve our control over this devastating complication.

publication date

  • December 1, 2007

Research

keywords

  • Antineoplastic Agents
  • Bone Density Conservation Agents
  • Bone Neoplasms
  • Drugs, Investigational

Identity

Scopus Document Identifier

  • 38849181180

Digital Object Identifier (DOI)

  • 10.3816/cbc.2007.s.010

PubMed ID

  • 18282368

Additional Document Info

volume

  • 8 Suppl 1